GLSI - חובות ארוכי טווח של החברה Greenwich LifeSciences, Inc

The price action chart for Greenwich LifeSciences (GLSI) illustrates the performance of a company whose future revenue will be based on the implementation of cancer immunotherapy, specifically the GP2 drug targeting breast tumor recurrences. The business strategy relies on completing final vaccine tests for its subsequent launch. Meanwhile, long-term debt stands at 0.00, highlighting a capital shortage driven by costly research in the absence of profits.

Greenwich LifeSciences focuses on laboratory research for cancer vaccines, eliminating the need for capital-intensive industrial plants. The debt_long_co metric captures obligations with maturities exceeding one year, reflecting the long-term financial burden on the capital structure. Low leverage confirms the biotech's resilience to market shocks, whereas an increase in debt may signal expansion. By analyzing the company's long-term debt volume on GURU.Markets, an investor determines the balance between viability and investment leverage.